Praxis will complete the reimbursement application for Aridol in France and thereafter market the product to hospital specialists.
Alan Robertson, CEO of Pharmaxis, said: “We are delighted to announce this agreement and are looking forward to working with Praxis on developing the French market for Aridol.
“Aridol is a precisely engineered test that we believe will be an improvement on current practice. Aridol improves the identification of bronchial hyperresponsiveness which is one of the hallmarks of asthma.”